Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats

Chemico-Biological Interactions

Volumn 177, Issue 2, 2009, Pages 128-136

  Tanaka, Takuji ^a   Yasui, Yumiko ^a   Tanaka, Mayu ^b   Tanaka, Takahiro ^c   Oyama, Takeru ^a   Rahman, KM Wahidur ^d  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KINJO GAKUIN UNIVERSITY   (Japan)

^c KANSAI UNIVERSITY OF HEALTH SCIENCES   (Japan)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Colitis; Colorectal cancer; Melatonin; Rats

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZOXYMETHANE; CHOLESTEROL; DEXTRAN SULFATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; LEPTIN; LOW DENSITY LIPOPROTEIN; MELATONIN; STAT3 PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER INHIBITION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DYSPLASIA; FISCHER 344 RAT; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MUCOSA INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZOXYMETHANE; COLON; COLONIC NEOPLASMS; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; MELATONIN; MITOTIC INDEX; NF-KAPPA B; RATS; RATS, INBRED F344; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 57649225896     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.10.047     Document Type: Article

References (61)

1. Reiter R.J., Tan D.X., Korkmaz A., Erren T.C., Piekarski C., Tamura H., and Manchester L.C. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit. Rev. Oncog. 13 (2007) 303-328
2. Dziegiel P., Podhorska-Okolow M., and Zabel M. Melatonin: adjuvant therapy of malignant tumors. Med. Sci. Monit. 14 (2008) RA-64-RA-70
3. Robeva R., Kirilov G., Tomova A., and Kumanov P. Melatonin-insulin interactions in patients with metabolic syndrome. J. Pineal Res. 44 (2008) 52-56
4. Schernhammer E.S., Kroenke C.H., Laden F., and Hankinson S.E. Night work and risk of breast cancer. Epidemiology 17 (2006) 108-111
5. Viswanathan A.N., Hankinson S.E., and Schernhammer E.S. Night shift work and the risk of endometrial cancer. Cancer Res. 67 (2007) 10618-10622
6. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I., Fuchs C.S., and Colditz G.A. Night-shift work and risk of colorectal cancer in the nurses' health study. J. Natl. Cancer Inst. 95 (2003) 825-828
7. Anisimov V.N. Effects of exogenous melatonin-a review. Toxicol. Pathol. 31 (2003) 589-603
8. Anisimov V.N. The role of pineal gland in breast cancer development. Crit. Rev. Oncol. Hematol. 46 (2003) 221-234
9. Anisimov V.N., Kvetnoy I.M., Chumakova N.K., Kvetnaya T.V., Molotkov A.O., Pogudina N.A., Popovich I.G., Popuchiev V.V., Zabezhinski M.A., Bartsch H., and Bartsch C. Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors. Exp. Toxicol. Pathol. 51 (1999) 47-52
10. Anisimov V.N., Popovich I.G., Shtylik A.V., Zabezhinski M.A., Ben-Huh H., Gurevich P., Berman V., Tendler Y., and Zusman I. Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats. Exp. Toxicol. Pathol. 52 (2000) 71-76
11. Anisimov V.N., Popovich I.G., and Zabezhinski M.A. Melatonin and colon carcinogenesis. I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18 (1997) 1549-1553
12. Kossoy G., Ben-Hur H., Popovich I., Zabezhinski M., Anisimov V., and Zusman I. Melatonin and colon carcinogenesis. IV. Effect of melatonin on proliferative activity and expression of apoptosis-related proteins in the spleen of rats exposed to 1,2-dimethylhydrazine. Oncol. Rep. 7 (2000) 1401-1405
13. Rahman K.M.W., Sugie S., Watanabe T., Tanaka T., and Mori H. Chemopreventive effects of melatonin on diethylnitrosamine and phenobarbital-induced hepatocarcinogenesis in male F344 rats. Nutr. Cancer 47 (2003) 148-155
14. Kumar C.A., and Das U.N. Effect of melatonin on two stage skin carcinogenesis in Swiss mice. Med. Sci. Monit. 6 (2000) 471-475
15. Ruiz-Rabelo J.F., Vázquez R., Perea M.D., Cruz A., González R., Romero A., Muñoz-Villanueva M.C., Túnez I., Montilla P., Muntané J., and Padillo F.J. Beneficial properties of melatonin in an experimental model of pancreatic cancer. J. Pineal Res. 43 (2007) 270-275
16. Karbownik M., Lewinski A., and Reiter R.J. Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int. J. Biochem. Cell. Biol. 33 (2001) 735-753
17. Musatov S.A., Anisimov V.N., André V., Vigreux C., Godard T., and Sichel F. Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay). Cancer Lett. 138 (1999) 37-44
18. Blask D.E., Dauchy R.T., Sauer L.A., and Krause J.A. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25 (2004) 951-960
19. Blask D.E., Dauchy R.T., and Sauer L.A. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27 (2005) 179-188
20. Dong W.G., Mei Q., Yu J.P., Xu J.M., Xiang L., and Xu Y. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J. Gastroenterol. 9 (2003) 1307-1311
21. Li J.H., Yu J.P., Yu H.G., Xu X.M., Yu L.L., Liu J., and Luo H.S. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005 (2005) 185-193
22. Mayo J.C., Sainz R.M., Tan D.X., Hardeland R., Leon J., Rodriguez C., and Reiter R.J. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J. Neuroimmunol. 165 (2005) 139-149
23. WHO Media Centre, Cancer, Fact sheet No. 297, WHO, 2006.
24. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
25. Rubin D.T., and Parekh N. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr. Treat. Opt. Gastroenterol. 9 (2006) 211-220
26. Tanaka T., Kohno H., Suzuki R., Yamada Y., Sugie S., and Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94 (2003) 965-973
27. Suzuki R., Kohno H., Sugie S., Nakagama H., and Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 27 (2006) 162-169
28. Suzuki R., Kohno H., Sugie S., and Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci. 95 (2004) 721-727
29. Suzuki R., Miyamoto S., Yasui Y., Sugie S., and Tanaka T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer 7 (2007) 84
30. Kohno H., Suzuki R., Curini M., Epifano F., Maltese F., Gonzales S.P., and Tanaka T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int. J. Cancer 118 (2006) 2936-2942
31. Kohno H., Suzuki R., Yasui Y., Miyamoto S., Wakabayashi K., and Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin. Cancer Res. 13 (2007) 2519-2525
32. Kohno H., Suzuki R., Sugie S., and Tanaka T. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 2005 (2005) 69-76
33. Tanaka T., Suzuki R., Kohno H., Sugie S., Takahashi M., and Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 26 (2005) 229-238
34. Tanaka T., Kohno H., Suzuki R., Hata K., Sugie S., Niho N., Sakano K., Takahashi M., and Wakabayashi K. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 118 (2006) 25-34
35. Ohshima H., Tazawa H., Sylla B.S., and Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat. Res. 591 (2005) 110-122
36. D'Inca R., Cardin R., Benazzato L., Angriman I., Martines D., and Sturniolo G.C. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm. Bowel Dis. 10 (2004) 23-27
37. Chan E.P., and Lichtenstein G.R. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol. Clin. N. Am. 35 (2006) 675-712
38. Cho Y.M., Imai T., Ota Y., Hasumura M., Takami S., Hirose M., and Nishikawa A. A new medium-term rat colorectal bioassay applying neoplastic lesions as end points for detection of carcinogenesis modifiers effects with weak or controversial modifiers. Toxicol. Pathol. 36 (2008) 459-464
39. T. Tanaka, H. Kohno, S. Yoshitani, S. Takashima, A. Okumura, A. Murakami, M. Hosokawa, Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats, Cancer Res. 61 (2001), 2424-2428.
40. Janakiram N.B., and Rao C.V. Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol. Sin. 29 (2008) 1-20
41. Y. Yasui, M. Kim, T. Tanaka, Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets, Curr. Enzyme Inhib., (2009) in press.
42. Ward J.M. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab. Invest. 30 (1974) 505-513
43. Yasui Y., Suzuki R., Miyamoto S., Tsukamoto T., Sugie S., Kohno H., and Tanaka T. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int. J. Cancer 121 (2007) 2331-2339
44. Anisimov V.N., Popovich I.G., Zabezhinski M.A., Anisimov S.V., Vesnushkin G.M., and Vinogradova I.A. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim. Biophys. Acta 1757 (2006) 573-589
45. Sener G., Balkan J., Cevikbaş U., Keyer-Uysal M., and Uysal M. Melatonin reduces cholesterol accumulation and prooxidant state induced by high cholesterol diet in the plasma, the liver and probably in the aorta of C57BL/6J mice. J. Pineal Res. 36 (2004) 212-216
46. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., and Sethi G. Inflammation and cancer: how hot is the link?. Biochem. Pharmacol. 72 (2006) 1605-1621
47. Deng W.G., Tang S.T., Tseng H.P., and Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108 (2006) 518-524
48. Kohno H., Suzuki R., Sugie S., and Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5 (2005) 46
49. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
50. Dong M., Guda K., Nambiar P.R., Rezaie A., Belinsky G.S., Lambeau G., Giardina C., and Rosenberg D.W. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 24 (2003) 307-315
51. Inan M.S., Place R., Tolmacheva V., Wang Q.S., Hubbard A.K., Rosenberg D.W., and Giardina C. IkappaBbeta-related proteins in normal and transformed colonic epithelial cells. Mol. Carcinog. 29 (2000) 25-36
52. Inan M.S., Tolmacheva V., Wang Q.S., Rosenberg D.W., and Giardina C. Transcription factor NF-kappaB participates in regulation of epithelial cell turnover in the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G1282-G1291
53. Tong X., Yin L., Washington R., Rosenberg D.W., and Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol. Cell. Biochem. 265 (2004) 171-183
54. Kusaba T., Nakayama T., Yamazumi K., Yakata Y., Yoshizaki A., Nagayasu T., and Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma, correlation with clinicopathological factors. J. Clin. Pathol. 58 (2005) 833-838
55. Fenton J.I., Hursting S.D., Perkins S.N., and Hord N.G. Interleukin-6 production by leptin treatment promotes cell proliferation in an Apc(Min/+) colon epithelial cell line. Carcinogenesis 27 (2006) 1507-1515
56. Li J.H., Zhou W., Liu K., Li H.X., and Wang L. Melatonin reduces the expression of chemokines in rat with trinitrobenzene sulfonic acid-induced colitis. Saudi Med. J. 29 (2008) 1088-1094
57. Ohta Y., Kongo-Nishimura M., Imai Y., Matsura T., Kitagawa A., and Yamada K. alpha-Tocopherol protects against alpha-naphthylisothiocyanate-induced hepatotoxicity in rats less effectively than melatonin. Chem. Biol. Interact. 131 (2006) 115-124
58. Ohta Y., Kongo-Nishimura M., Imai Y., and Kitagawa A. Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment. J. Pineal Res. 42 (2007) 159-165
59. Nishida S., Segawa T., Murai I., and Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J. Pineal Res. 32 (2002) 26-33
60. Sanchez-Mateos S., Alonso-Gonzalez C., Gonzalez A., Martinez-Campa C.M., Mediavilla M.D., Cos S., and Sanchez-Barcelo E.J. Melatonin and estradiol effects on food intake, body weight, and leptin in ovariectomized rats. Maturitas 58 (2007) 91-101
61. Hussein M.R., Ahmed O.G., Hassan A.F., and Ahmed M.A. Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model. Int. J. Exp. Pathol. 88 (2007) 19-29